Member Info for SGD27

A couple of the 50k trades are mine. Sold in the morning, bought back around lunchtime.

Hi Tony,
I have also contacted the company, but specifically in connection with the Amiens trial (see posts earlier today). Will share any response.

@Vorag : Thanks, just to clarify - does "filing date" = "submission date"?

@Joshholdforgold & mattw007 : Yes, we did discuss it a while ago, and noted that the existing patents covered both 1a & 1b. And as you say, months behind. So no, it's not a worry, particularly now, just curious how it fits in - maybe they're collaborating in some way?

I wonder if the new July patent was partly a reaction to the proposed Amiens trial (inhaled IFN-beta1b).

https://clinicaltrials.gov/ct2/show/NCT04469491

(If this was already posted today, apols I must have missed it.)

https://www.synairgen.com/wp-content/uploads/2020/09/Synairgen-COPD-SNG001-interim-trial-data-to-support-COVID-19-program-Read-Only-Compatibility-Mode.pdf

A bit more background on how the trial was set up :

https://www.trialsitenews.com/promising-covid-19-study-supported-by-lightning-fast-etmf-deployment/

I'm sympathetic to Awonda because when I first invested in SNG back in 2016, one of the first questions I asked here was whether the IP was watertight!

Awonda, according to my notes we had a discussion about this back in mid-April. Not sure if it's at all practical to scroll back that far, so you might just have to take our word for it that it's OK.

Sorry, typo:
( not " in last line

Doesn't this cover everything we want?

https://patents.justia.com/patent/9421243

"Therapy for influenza like illness
Mar 10, 2011 - SYNAIRGEN RESEARCH LIMITED
An agent selected from: (a) interferon-ß (IFN-ß); (b) an agent that increases IFN-ß expression; or (c) a polynucleotide which is capable of expressing (a) or (b); for use in the treatment of individuals with lower respiratory tract illness that has developed during or following an established ILI, wherein said treatment is by airway delivery of said medicament."

"The definition of "ILI" would appear to cover COVID19.)

OK, I'll assume that means "of 100 people infected only expect 1 to die". I just wanted to make was that our sample of 101 was of hospitalised patients, therefore the death rate would be expected to be higher, so it isn't inconsistent.

Thanks, tomvisual. Was that "out of 100 people" infected or hospitalised or something else?

My theory is that it will be Bay State Silver because that was NOT included in the presentation Appendix for "Projects Available for Sale or Joint Venture"! Also, am I right in recalling that it was the most recent of the PM projects given any serious attention?

https://www.theguardian.com/world/2020/aug/24/six-of-the-most-promising-treatments-for-covid-19-so-far

Check out no 6.

I accidentally missed off the footnote :

* Assuming the Broker Option is fully taken up.

But TBH I'll be surprised if it isn't over-subscribed.

Just for interest, here's an updated recent placings history:

Aug 2020: 357m @ 0.28 = £1m *
Feb 2020: 180m @ 0.11 = £200k
Nov 2019: 350m @ 0.10 = £350k
Jan 2019: 292m @ 0.12 = £350k
Jul 2018: 286m @ 0.14 = £400k
Dec 2017: 333m @ 0.15 = £500k
Jun 2017: 325m @ 0.10 = £325k
Mar 2017: 250m @ 0.10 = £250k
Jan 2017: 61m @ 0.10 = £61k
May 2016: 250m @ 0.12 = £300k
Apr 2016: 109m @ 0.11 = £120k

@Mineralex : Hi, an update for your list. I'm now up to 32m.

I think you're confusing LOXL2 & PXS5505A. They're two quite separate programs.

I've phoned HL, and they've admitted there are 'intermittent' issues with their live prices at the moment.

Likewise Twiggy, I'm on HL too. Their live prices have been a bit flaky recently, so maybe that's it.